T1	Participants 407 429	in Australia and China
T2	Participants 760 801	33 protocol compliant Brisbane recipients
T3	Participants 1033 1075	102 protocol compliant Brisbane recipients
T4	Participants 1360 1425	52 protocol compliant placebo immunotherapy recipients in Wenzhou
T6	Participants 1689 1728	168 Wenzhou protocol compliant subjects
T7	Participants 1937 1990	patients for whom destructive therapy is unsuccessful
T5	Participants 1551 1566	Wenzhou subject
T8	Participants 1590 1607	Brisbane subjects
